温化方对慢性HBV携带者Fibroscan弹性值及血清IL10、IL17表达水平的影响

Effects of Wenhua Fang on Chronic HBV Carriers Fibroscan Elasticity and Serum IL10、IL17 Expression Level

目的观察温化方对慢性乙型肝炎携带者HBV-DNA、Fibroscan弹性值及IL10、IL17表达水平的影响,探讨温化方的保肝作用及部分机制。方法采取随机、单盲、空白对照的研究方法,将30例慢性HBV携带者随机分为治疗组和对照组,治疗组16例采用温化方,对照组14例口服安慰剂,治疗12周后,观察慢性乙型肝炎携带HBV-DNA、Fibroscan弹性值及血清IL10、IL17水平变化情况。结果治疗组患者治疗后HBV-DNA、Fibroscan弹性值明显降低、血清IL10、IL17水平明显升高,(P<0.05);对照组治疗前后无明显变化,差异无统计学意义(P>0.05)。结论温化方对脾肾阳虚型慢性乙型肝炎携带者具有明显的抗病毒作用,同时对携带者的肝组织纤维化具有明显改善作用,其作用可能与通过平衡提高慢性乙型肝炎携带者IL10、IL17水平有关。

Objective To observe the effect of Wenhua Fang on chronic HBV carriers HBV-DNA copies,Fibroscan elasticity and IL10,IL17 expression level. and to explore the hepatoprotective mechanism of Wenhua fang. Methods This paper chose a randomized,single-blind,blank control way of study. 30 chronic HBV carriers were randomly divided into treatment group and control group,Treatment group use Wenhua Fang and control group use placebo for 12 weeks. Observing all cases＇ HBV-DNA copies,Fibroscan elasticity and IL10,IL17 expression level. Results The HBV-DNA copies,Fibroscan elasticity and serum IL10,IL17 expression levels are significantly increased in treatment group,（P〈0. 05）;and manifest no statistical significance（P〉0. 05）in control group. Conclusion Wenhua fang shows significant antiviral effect on chronic HBV carriers with asdthenic splenonephro-yang.It can also alleviate liver fibrosis of chronic HBV carriers evidently. These effects may be associated with an even improving of serum IL10,IL17 expression levels in chronic HBV carries.